Index RUT
P/E -
EPS (ttm) -3.34
Insider Own 23.22%
Shs Outstand 61.42M
Perf Week -1.98%
Market Cap 745.37M
Forward P/E -
EPS next Y -2.75
Insider Trans -0.77%
Shs Float 52.46M
Perf Month 6.23%
Income -220.01M
PEG -
EPS next Q -0.83
Inst Own 87.77%
Short Float 9.96%
Perf Quarter 28.35%
Sales 0.00M
P/S -
EPS this Y 1.90%
Inst Trans -0.71%
Short Ratio 6.39
Perf Half Y 33.05%
Book/sh 6.24
P/B 1.75
EPS next Y 13.62%
ROA -38.64%
Short Interest 5.23M
Perf Year -34.36%
Cash/sh 6.87
P/C 1.59
EPS next 5Y -
ROE -46.79%
52W Range 4.92 - 17.89
Perf YTD 29.42%
Dividend Est. -
P/FCF -
EPS past 5Y -19.52%
ROI -44.13%
52W High -39.02%
Beta 1.21
Dividend TTM -
Quick Ratio 13.46
Sales past 5Y 0.00%
Gross Margin -
52W Low 121.75%
ATR (14) 0.67
Dividend Ex-Date -
Current Ratio 13.46
EPS Y/Y TTM -8.24%
Oper. Margin 0.00%
RSI (14) 55.53
Volatility 7.13% 6.49%
Employees 331
Debt/Eq 0.18
Sales Y/Y TTM -
Profit Margin -
Recom 1.10
Target Price 15.00
Option/Short Yes / Yes
LT Debt/Eq 0.17
EPS Q/Q -4.08%
Payout -
Rel Volume 4.56
Prev Close 11.23
Sales Surprise -
EPS Surprise 8.98%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 817.51K
Price 10.91
SMA20 3.68%
SMA50 6.33%
SMA200 31.17%
Trades
Volume 3,730,522
Change -2.85%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Initiated
ROTH MKM
Buy
$17
Apr-17-23 Resumed
Piper Sandler
Overweight
$44
Nov-19-21 Initiated
Piper Sandler
Overweight
$52
Oct-15-21 Resumed
BTIG Research
Buy
$60
Nov-17-20 Initiated
BTIG Research
Buy
$60
Nov-02-20 Initiated
Jefferies
Buy
$67
Oct-15-20 Upgrade
H.C. Wainwright
Neutral → Buy
$25 → $54
Jul-01-20 Downgrade
H.C. Wainwright
Buy → Neutral
$25
May-05-20 Initiated
Barclays
Overweight
$21
Sep-04-19 Initiated
ROTH Capital
Buy
$20
Jul-23-19 Initiated
Chardan Capital Markets
Buy
$28
Jul-12-19 Upgrade
JP Morgan
Neutral → Overweight
$27 → $26
Jul-08-19 Initiated
H.C. Wainwright
Buy
$26
Apr-25-19 Initiated
Wedbush
Outperform
$24
Jan-23-19 Downgrade
JP Morgan
Overweight → Neutral
Aug-14-18 Initiated
Leerink Partners
Outperform
$25
Aug-14-18 Initiated
JP Morgan
Overweight
$26
Show Previous Ratings
Sep-15-24 09:45AM
Sep-09-24 08:00AM
Sep-05-24 08:00AM
Aug-22-24 08:00AM
Aug-14-24 04:33PM
(Pharmaceutical Technology)
08:00AM
Loading…
Aug-13-24 08:00AM
Aug-08-24 08:00AM
Jul-30-24 04:01PM
Jun-13-24 08:30AM
Jun-07-24 09:03AM
08:00AM
Jun-06-24 12:16PM
07:00AM
Jun-03-24 08:00AM
May-23-24 05:00PM
01:53PM
Loading…
May-16-24 01:53PM
08:00AM
Apr-07-24 05:00PM
Apr-04-24 08:00AM
Mar-26-24 07:30AM
Mar-11-24 09:55AM
Mar-08-24 12:00PM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Feb-27-24 03:30AM
Feb-23-24 09:55AM
Feb-08-24 08:42AM
08:00AM
Jan-22-24 10:54AM
Jan-16-24 03:59AM
08:00AM
Loading…
Dec-28-23 08:00AM
Dec-05-23 07:32AM
07:10AM
07:00AM
Nov-13-23 09:55AM
Nov-08-23 09:10AM
Nov-07-23 08:00AM
Nov-03-23 07:30PM
Oct-17-23 03:00AM
Sep-19-23 04:01PM
08:00AM
Sep-14-23 01:23PM
Aug-03-23 08:00AM
Aug-01-23 08:00AM
Jul-31-23 04:01PM
Jul-28-23 03:57PM
Jul-20-23 08:00AM
Jun-06-23 10:00AM
Jun-05-23 08:00AM
Jun-03-23 02:15PM
Jun-01-23 04:01PM
May-25-23 05:00PM
May-18-23 08:00AM
May-17-23 10:02AM
May-09-23 08:00AM
Mar-31-23 09:35AM
Mar-08-23 08:00AM
Feb-24-23 09:35AM
Feb-09-23 08:50AM
08:00AM
Feb-07-23 08:00AM
Jan-06-23 09:55AM
09:04AM
08:50AM
Jan-05-23 05:44AM
(American City Business Journals)
Jan-04-23 08:05AM
08:00AM
Jan-03-23 08:00AM
Dec-14-22 10:46AM
Dec-12-22 02:36PM
Dec-08-22 09:04PM
Dec-07-22 04:04PM
10:05AM
07:00AM
06:30AM
Nov-23-22 08:00AM
Nov-22-22 08:00AM
Nov-03-22 08:00AM
Nov-02-22 04:01PM
Oct-14-22 01:52PM
Oct-07-22 08:00AM
Aug-24-22 07:58AM
Aug-06-22 09:36AM
Aug-04-22 08:00AM
Aug-01-22 04:01PM
Jun-03-22 08:00AM
Jun-02-22 08:00AM
May-30-22 06:42AM
May-26-22 05:15PM
May-19-22 08:00AM
May-03-22 08:55AM
Apr-14-22 01:35PM
Mar-30-22 07:00AM
Mar-21-22 08:00AM
Feb-11-22 08:00AM
Feb-03-22 08:00AM
Jan-31-22 04:01PM
Jan-10-22 07:00AM
Jan-04-22 08:00AM
Dec-17-21 09:35AM
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hill Emily Luisa Chief Financial Officer Aug 16 '24 Sale 10.18 8,938 90,989 101,057 Aug 19 08:00 PM Xynos Konstantinos Chief Medical Officer Jun 07 '24 Sale 7.50 15,881 119,108 117,131 Jun 10 08:30 PM Sarchi Christopher Chief Commercial Officer May 16 '24 Sale 6.47 2,218 14,350 92,252 May 20 08:06 PM Schwendenman Andrew Chief Accounting Officer May 16 '24 Sale 6.47 2,298 14,868 38,238 May 20 08:06 PM Love Colin Chief Operating Officer May 16 '24 Sale 6.47 17,615 113,969 777,345 May 20 08:05 PM Astley-Sparke Philip Executive Chairman May 16 '24 Sale 6.47 37,928 245,394 1,487,350 May 20 08:04 PM Coffin Robert Director May 16 '24 Sale 6.47 11,464 74,172 1,821,872 May 20 08:02 PM Patel Sushil Chief Executive Officer May 16 '24 Sale 6.47 20,194 130,655 212,014 May 20 08:01 PM Xynos Konstantinos Chief Medical Officer May 16 '24 Sale 6.47 6,367 41,194 133,012 May 20 08:00 PM Xynos Konstantinos Chief Medical Officer Nov 16 '23 Sale 10.92 7,313 79,858 112,714 Nov 17 08:01 PM Sarchi Christopher Chief Commercial Officer Nov 16 '23 Sale 10.92 5,255 57,385 72,245 Nov 17 08:00 PM
Index RUT
P/E -
EPS (ttm) -6.32
Insider Own 3.29%
Shs Outstand 75.71M
Perf Week 7.80%
Market Cap 2.82B
Forward P/E -
EPS next Y -4.15
Insider Trans -1.11%
Shs Float 74.40M
Perf Month 7.99%
Income -479.52M
PEG -
EPS next Q -1.51
Inst Own 103.39%
Short Float 7.56%
Perf Quarter 0.33%
Sales 900.45M
P/S 3.13
EPS this Y 37.58%
Inst Trans 2.02%
Short Ratio 8.21
Perf Half Y 21.45%
Book/sh -12.75
P/B -
EPS next Y 20.59%
ROA -29.47%
Short Interest 5.63M
Perf Year 43.52%
Cash/sh 14.21
P/C 2.58
EPS next 5Y -9.51%
ROE -
52W Range 17.53 - 40.69
Perf YTD 32.95%
Dividend Est. -
P/FCF -
EPS past 5Y -24.94%
ROI -
52W High -9.95%
Beta 0.65
Dividend TTM -
Quick Ratio 2.17
Sales past 5Y 29.08%
Gross Margin 71.23%
52W Low 109.01%
ATR (14) 1.58
Dividend Ex-Date -
Current Ratio 2.23
EPS Y/Y TTM 25.01%
Oper. Margin -21.37%
RSI (14) 66.80
Volatility 4.14% 4.45%
Employees 995
Debt/Eq -
Sales Y/Y TTM 9.98%
Profit Margin -53.25%
Recom 2.47
Target Price 39.71
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 51.43%
Payout -
Rel Volume 1.34
Prev Close 36.16
Sales Surprise 1.87%
EPS Surprise -15.19%
Sales Q/Q -12.68%
Earnings Aug 08 AMC
Avg Volume 685.43K
Price 36.64
SMA20 8.34%
SMA50 10.02%
SMA200 19.16%
Trades
Volume 919,978
Change 1.33%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-04-24 Initiated
Robert W. Baird
Outperform
$44
Aug-26-24 Resumed
UBS
Buy
$47
May-20-24 Upgrade
Raymond James
Underperform → Mkt Perform
Dec-19-23 Downgrade
Morgan Stanley
Equal-Weight → Underweight
$28
Dec-08-23 Initiated
Wells Fargo
Overweight
$37
Oct-30-23 Upgrade
Oppenheimer
Perform → Outperform
$165
Oct-27-23 Downgrade
Citigroup
Neutral → Sell
$29 → $17
Oct-06-23 Downgrade
Truist
Buy → Hold
$45 → $25
Sep-18-23 Downgrade
Citigroup
Buy → Neutral
$55 → $28
Sep-15-23 Downgrade
Raymond James
Outperform → Underperform
Mar-17-23 Initiated
SVB Securities
Market Perform
$48
Dec-14-22 Initiated
Goldman
Sell
$35
Sep-12-22 Initiated
Jefferies
Buy
$62
Sep-09-22 Initiated
Morgan Stanley
Equal-Weight
$54
Sep-01-22 Initiated
Citigroup
Buy
$70
Apr-04-22 Resumed
Cantor Fitzgerald
Overweight
$64 → $63
Oct-18-21 Downgrade
BofA Securities
Neutral → Underperform
$38
Apr-26-21 Resumed
Credit Suisse
Neutral
$54
Mar-29-21 Upgrade
RBC Capital Mkts
Underperform → Sector Perform
$47
Feb-12-21 Downgrade
BofA Securities
Buy → Neutral
Show Previous Ratings
Sep-12-24 04:30PM
Aug-28-24 04:30PM
Aug-19-24 03:33PM
(Investor's Business Daily)
Aug-08-24 05:15PM
04:09PM
(Associated Press Finance)
04:01PM
Loading…
04:01PM
Aug-06-24 09:15AM
Jul-30-24 08:00AM
Jul-25-24 04:30PM
10:02AM
Jul-01-24 08:00AM
Jun-28-24 04:08PM
(Investor's Business Daily) -11.77%
08:53AM
(Investor's Business Daily)
07:49AM
06:00AM
04:44AM
Loading…
Jun-24-24 04:44AM
Jun-21-24 04:30PM
Jun-20-24 08:19AM
06:30AM
Jun-04-24 06:00AM
May-29-24 08:00AM
May-28-24 08:30AM
May-25-24 02:41AM
May-21-24 12:26PM
10:34AM
May-20-24 04:05PM
(Investor's Business Daily) +21.23%
12:36PM
12:20PM
08:57AM
08:45AM
07:45AM
Loading…
07:45AM
May-14-24 09:10AM
08:51AM
08:26AM
07:30AM
May-02-24 08:00AM
May-01-24 02:45PM
(Investor's Business Daily) +6.25%
Apr-30-24 12:25PM
Apr-29-24 06:11AM
Apr-26-24 03:57PM
11:16AM
07:11AM
(Thomson Reuters StreetEvents)
03:35AM
Apr-25-24 08:56PM
08:00PM
05:39PM
04:53PM
(Associated Press Finance)
04:05PM
Apr-23-24 04:30PM
Apr-18-24 10:01AM
Apr-11-24 08:00AM
Mar-28-24 08:30AM
Mar-25-24 10:00AM
Mar-20-24 02:00PM
Mar-19-24 07:30AM
Mar-02-24 08:56AM
Mar-01-24 06:51AM
(Thomson Reuters StreetEvents) +13.34%
Feb-29-24 06:00PM
05:20PM
04:33PM
04:30PM
(Associated Press Finance)
04:05PM
Feb-27-24 05:20PM
Feb-26-24 09:16AM
Feb-22-24 04:30PM
Feb-15-24 08:00AM
Feb-13-24 10:00AM
Feb-11-24 01:45AM
Jan-26-24 04:06PM
(Investor's Business Daily)
11:45AM
(Investor's Business Daily)
10:18AM
(Investor's Business Daily)
Jan-25-24 04:51PM
04:20PM
04:05PM
Jan-24-24 07:02PM
Jan-12-24 01:02AM
Jan-08-24 09:26AM
Jan-03-24 08:00AM
Dec-20-23 09:41AM
Dec-15-23 05:01PM
Dec-14-23 04:30PM
Dec-05-23 04:15PM
Nov-14-23 03:58PM
Nov-03-23 04:30PM
Oct-30-23 09:03AM
Oct-27-23 11:22AM
(Thomson Reuters StreetEvents) -22.71%
10:01AM
08:33AM
07:15AM
02:38AM
Oct-26-23 07:30PM
06:10PM
05:30PM
04:25PM
(Associated Press Finance)
04:05PM
Oct-24-23 10:00AM
Oct-19-23 07:02PM
10:01AM
08:00AM
Oct-16-23 04:30PM
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gravier Pierre CHIEF FINANCIAL OFFICER Jul 16 '24 Sale 34.02 2,269 77,200 53,531 Jul 18 05:20 PM ZELDIS JEROME B Director May 22 '24 Option Exercise 26.42 20,000 528,400 34,500 May 24 05:20 PM ZELDIS JEROME B Director May 22 '24 Sale 38.24 20,000 764,800 14,500 May 24 05:20 PM Golden Lee Scott EVP & CHIEF MEDICAL OFFICER May 07 '24 Sale 32.82 175 5,744 59,813 May 08 05:20 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Apr 19 '24 Sale 24.89 3,361 83,669 225,807 Apr 22 05:20 PM Pauwels Eric CHIEF EXECUTIVE OFFICER Apr 17 '24 Sale 25.14 787 19,781 67,694 Apr 19 05:20 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Apr 17 '24 Sale 25.14 1,307 32,851 229,168 Apr 19 05:20 PM Golden Lee Scott EVP & CHIEF MEDICAL OFFICER Apr 02 '24 Sale 28.37 526 14,923 59,988 Apr 04 05:16 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 30 '24 Sale 27.25 618 16,841 61,202 Feb 01 04:18 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 30 '24 Sale 27.25 28 763 3,706 Feb 01 04:18 PM Boulding Mark Elliott EXEC. VP AND CLO Jan 30 '24 Sale 27.25 794 21,637 71,189 Feb 01 04:17 PM Pauwels Eric CHIEF BUSINESS OFFICER Jan 30 '24 Sale 27.25 366 9,974 44,181 Feb 01 04:16 PM Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER Jan 30 '24 Sale 27.25 318 8,666 35,528 Feb 01 04:15 PM Jacobson Allan Steven Director Jan 22 '24 Option Exercise 27.05 10,000 270,500 22,348 Jan 24 04:30 PM Jacobson Allan Steven Director Jan 22 '24 Sale 27.38 10,000 273,804 12,348 Jan 24 04:30 PM Utter Christine Marie SVP, FINANCE & CAO Jan 09 '24 Sale 29.01 1,653 47,961 35,846 Jan 10 04:11 PM Utter Christine Marie SVP, FINANCE & CAO Jan 08 '24 Sale 28.64 1,188 34,025 37,499 Jan 10 04:11 PM SCHMERTZLER MICHAEL Director Jan 08 '24 Sale 27.81 1,500 41,715 115,266 Jan 10 04:10 PM Pauwels Eric CHIEF BUSINESS OFFICER Jan 09 '24 Sale 29.01 2,065 59,916 44,547 Jan 10 04:09 PM Pauwels Eric CHIEF BUSINESS OFFICER Jan 08 '24 Sale 28.64 1,569 44,937 46,612 Jan 10 04:09 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Jan 09 '24 Sale 29.01 5,443 157,928 160,475 Jan 10 04:08 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Jan 08 '24 Sale 28.64 2,237 64,068 165,918 Jan 10 04:08 PM Golden Lee Scott CHIEF MEDICAL OFFICER Jan 09 '24 Sale 29.01 1,225 35,543 37,914 Jan 10 04:06 PM Golden Lee Scott CHIEF MEDICAL OFFICER Jan 08 '24 Sale 28.64 775 22,196 39,139 Jan 10 04:06 PM Boulding Mark Elliott EXEC. VP AND CLO Jan 09 '24 Sale 29.01 1,938 56,231 71,983 Jan 10 04:04 PM Boulding Mark Elliott EXEC. VP AND CLO Jan 08 '24 Sale 28.64 1,457 41,729 73,921 Jan 10 04:04 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 09 '24 Sale 29.01 1,521 44,132 61,820 Jan 10 04:03 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 08 '24 Sale 28.64 1,236 35,399 63,341 Jan 10 04:03 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 09 '24 Sale 29.01 100 2,901 3,734 Jan 10 04:03 PM Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Jan 08 '24 Sale 28.64 53 1,518 3,834 Jan 10 04:03 PM Klein Matthew B. CHIEF EXECUTIVE OFFICER Jan 05 '24 Sale 27.15 10,107 274,393 168,155 Jan 09 04:29 PM Gravier Pierre CHIEF FINANCIAL OFFICER Dec 12 '23 Buy 25.81 7,700 198,736 33,700 Dec 14 04:38 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite